RasGRP1 gene of mouse and application of RasGRP1 gene point mutation mouse model

By constructing a mouse model of point mutation of RasGRP1 gene, the role of the RasGRP1 gene in T cell regulation and tumor immunity was studied, and the problem of insufficient research on point mutation of RasGRP1 in the existing technology was solved, and new genetic resources and tumor immunity research were provided. Model reveals the regulatory effect of RasGRP1 gene on tumor growth and T cell function.

CN118910071APending Publication Date: 2024-11-08HUNAN ACAD OF CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411137976.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

There are few reports on the prior art about the RasGRP1 point mutation in the process of T cell regulation and immune response, and there is a lack of effective mouse models for tumor immune research.

Method used

By constructing a point mutation mouse model of exon 1083 of the mouse RasGRP1 gene mutation from cytosine C to adenine A, resulting in aspartic acid to glutamate, to study the function of the RasGRP1 gene Its role in tumor immunity.

Benefits of technology

New genetic resources and animal models are provided, revealing the regulatory effect of point mutations in RasGRP1 gene on T cell function and tumor development, significantly increasing tumor growth and tumor weight, and attenuating the infiltration and activity of T cells in tumors, with good The application value of the tumor immunity research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910071A_ABST
    Figure CN118910071A_ABST
Patent Text Reader

Abstract

The invention relates to an application of a mouse RasGRP1 gene and a mouse model with RasGRP1 gene point mutation, and belongs to the technical field of biomedicine and clinic. According to the mutant mouse obtained by performing mutation treatment and genetic screening on the mouse, the proportion of peripheral blood T cells of the mutant mouse is reduced, and the proportion of memory T cells is increased. Through exon capture and sequencing, it is determined that the 1083th nucleotide of the ninth exon of the mouse RasGRP1 gene is mutated into adenine A from cytosine C, and the corresponding 361th amino acid is mutated into glutamic acid from aspartic acid. A tumor-bearing experiment carried out by using a mouse with RasGRP1 gene point mutation shows that the RasGRP1 gene point mutation leads to weakening of T cell infiltration in a mouse tumor and aggravates the depletion phenotype of the mouse tumor. It is fully indicated that the RasGRP1 gene is a key gene in tumor immunity, and a brand new regulation effect of the RasGRP1 gene point mutation on T cells is disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to an application of a mouse RasGRP1 gene and a mouse model of a RasGRP1 gene point mutation, and belongs to the field of biomedicine and clinical technology. Background Art

[0002] Cancer, also known as malignant tumor, is caused by malignant cell proliferation and is invasive and metastatic. The cause of cancer is usually due to the long-term combined effects of chemical, physical, viral and other factors on the body, which triggers a series of abnormal genetic changes. The clinical symptoms of cancer are related to factors such as the site of onset, the size of the lesion, and whether it has metastasized. There may be no obvious symptoms in the early stages. As the disease progresses, local symptoms such as lumps, pain, bleeding, and obstruction may appear, as well as systemic symptoms such as fever, fatigue, anemia, and weight loss.

[0003] Common treatments for cancer include surgery, chemotherapy, radiotherapy, etc., and when necessary, targeted therapy, biological therapy and other methods are also combined. With the study of the occurrence and development of various cancers, cancer immunotherapy has gradually emerged and become an effective treatment method. There are three main types of cancer immunotherapy: cancer vaccines, adoptive cell therapy and immune regulation strategies. Among them, immunotherapy has become the fourth most promising cancer treatment method after surgery, chemotherapy and radiotherapy. Immune checkpoint blockade therapy has become one of the most popular immunotherapies today. This therapy has significantly changed the current pattern of cancer treatment, and PD-1 / PD-L1 immune blockade therapy is the most typical representative.

[0004] Professor Honjo Tasuku first discovered PD-1 in 1992. He isolated and identified the PD-1 gene from mouse lymphocytes and obtained mouse PD-1 protein. He then published in 2000 that PD-L1 protein is the ligand of PD-1. He also confirmed for the first time that PD-L1 inhibits T cell proliferation and cytokine secretion by binding to PD-1. The 2018 Nobel Prize in Physiology or Medicine was awarded to American scientist James Allison and Japanese scientist Honjo Tasuku in recognition of their discovery of "immune checkpoint therapy", a cancer therapy that inhibits negative immune regulation.

[0005] Programmed cell death receptor (PD-1) is an important immunosuppressive molecule that can downregulate the response of the immune system to avoid autoimmune diseases. PD-L1 and PD-L2 on the surface of tumor cells bind to PD-1 on T cells, causing tumor cells to gain immune escape. Therefore, inhibiting the binding between them through inhibitors can enable T cells to kill and eliminate tumor cells normally. In recent years, immune checkpoint inhibitors anti-PD-1 and anti-PD-L1 antibodies have been used to treat a variety of human tumors, such as melanoma, renal cell carcinoma, non-small cell lung cancer, and Hodgkin's lymphoma.

[0006] RasGRP1 mainly acts as an activator of Ras protein, thereby regulating the activity of downstream signaling pathways. Studies have shown that RasGRP1-deficient mice show thymocyte development disorders and a significant lack of mature single-positive thymocytes, which has a certain blocking effect on T cell development. After RasGRP1 gene knockout, TCR-Ras-Erk signaling is impaired, showing a decrease in αβT cells, accompanied by impaired Erk1 / 2 signals, but it does not significantly affect the number of γδT cells in the thymus, but will lead to an increase in the frequency of CD8+γδT cells in peripheral lymphoid organs. It can be seen that RasGRP1 plays an important role in the regulation of T cells and immune responses. At the same time, RasGRP1 is also becoming a potential target for the research and development of new immunomodulatory drugs. Drugs targeting RasGRP1 may be used to regulate T cell-mediated cellular immune responses and treat autoimmune diseases or cancer, but there are relatively few reports on RasGRP1 point mutations. Summary of the invention

[0007] The first purpose of the present invention is to provide a mouse RasGRP1 gene, and to provide a new point mutation sequence for the study of the function of the RasGRP1 gene in the prior art.

[0008] The second purpose of the present invention is to provide a mouse model with a RasGRP1 gene point mutation for use in tumor immunity research, thereby providing a new animal model for the study of tumor immunity mechanisms in the prior art.

[0009] In order to achieve the above object, the technical solution of a mouse RasGRP1 gene of the present invention is:

[0010] A mouse RasGRP1 gene, wherein the nucleotide sequence of exon 9 of the RasGRP1 gene is shown as SEQ ID NO.1.

[0011] The beneficial effect of the above technical scheme is that the mouse RasGRP1 gene of the present invention is a pioneering invention. The present invention first performs mutation treatment on mice, and genetically screens the mutant mice to find that the proportion of peripheral blood T cells of the mutant mice decreases, while the proportion of memory T cells increases. Then, through exon capture and sequencing, it is determined that the nucleotide at position 1083 of exon 9 of the mouse RasGRP1 gene mutates from cytosine C to adenine A, resulting in the corresponding 361st amino acid mutation from aspartic acid to glutamic acid. The mouse RasGRP1 gene provided by the present invention is a new point mutation RasGRP1 gene, which provides a new and available genetic resource for studying the effect of point mutations on the function of the RasGRP1 gene.

[0012] The specific information of the RasGRP1 gene is as follows:

[0013] MGI (Mouse Genome Informatics): 1314635;

[0014] NCBI Gene: 19419; Transcript: ENSMUST00000102534.11, Rasgrp1-201.

[0015] In order to achieve the above-mentioned purpose, the technical scheme of the present invention for applying a mouse model with RasGRP1 gene point mutation in tumor immunity research is:

[0016] A mouse model with a RasGRP1 gene point mutation is used in tumor immunity research. The nucleotide at position 1083 of exon 9 of the RasGRP1 gene in the mouse model mutates from cytosine C to adenine A.

[0017] The beneficial effect of the above technical solution is that: the present invention first performs mutation treatment on mice, and genetically screens the mutant mice to obtain them, and finds that the proportion of peripheral blood T cells in the mutant mice decreases, while the proportion of memory T cells increases. Then, through exon capture and sequencing, it is determined that the nucleotide at position 1083 of exon 9 of the mouse RasGRP1 gene mutates from cytosine C to adenine A, resulting in the corresponding amino acid 361 mutating from aspartic acid to glutamic acid. The present invention obtains a RasGRP1 gene point mutation mouse model for the first time, providing a new animal model for studying the RasGRP1 gene and T cell function, and T cells and tumor development.

[0018] Furthermore, the present invention cultured the obtained mice with RasGRP1 gene point mutation and conducted tumor-bearing experiments, and found that compared with wild-type mice, the tumors in mice with RasGRP1 gene point mutation grew rapidly, and the tumor weight increased significantly, the percentage and absolute count of T cells in the tumor were significantly reduced, and their exhaustion phenotype was aggravated. This reveals the new regulatory effect of RasGRP1 gene point mutation on T cells in tumors, which fully demonstrates that the mouse model with RasGRP1 gene point mutation has good application value in the study of tumor immunity.

[0019] Specifically, the mouse model of the RasGRP1 gene point mutation of the present invention can be constructed using gene editing methods such as CRISPR / Cas9 technology, zinc finger nuclease technology and TALEN technology.

[0020] As a further improvement, the tumor immunity study includes the increase in tumor volume and weight after tumor bearing in the mouse model.

[0021] As a further improvement, the tumor immunity study includes the reduction of T cell percentage and absolute count in tumor after tumor bearing in mouse model.

[0022] As a further improvement, the tumor immunity study includes an increase in the percentage of PD-1 in CD4+T cells in tumors after tumor bearing in mouse models. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 The peripheral blood T cell flow cytometry analysis of mutant mice in Example 1 of the present invention (wherein (a) is a schematic diagram of the T cell flow cytometry gate, (b) is the percentage and absolute count of T cells, *** represents P < 0.001, **** represents P < 0.0001);

[0024] Figure 2 This is a flow cytometry analysis of peripheral blood memory T cells of mutant mice in Example 1 of the present invention (wherein (a) is a schematic diagram of the flow cytometry gate of memory T cells, (b) is the percentage and absolute count of memory T cells, **** represents P<0.0001);

[0025] Figure 3 The RasGRP1 gene mutation in the mouse with the RasGRP1 gene point mutation in Example 1 of the present invention (wherein (a) is agarose gel electrophoresis after PCR amplification of the point mutation site, and (b) is the positioning display of the RasGRP1 gene point mutation, and the bases and amino acids indicated in red represent the mutation);

[0026] Figure 4 The tumor volume and weight of tumor-bearing mice in Example 2 of the present invention are detected ((a) is a comparison of the growth volume of mouse tumors, (b) is a comparison of the weight of mouse tumors, * represents P < 0.05, ** represents P < 0.01);

[0027] Figure 5 The infiltration of T cells in the mouse tumor in Example 2 of the present invention ((a) is a schematic diagram of the T cell gate, (b) is the absolute count of immune cells (WBC), the percentage of T cells and the absolute count, *** represents P < 0.001, ns represents no significant difference);

[0028] Figure 6 The expression of PD-1 on T cells in mouse tumors in Example 2 of the present invention (wherein (a) is a schematic diagram of the gates on CD4+ and CD8+ T cells, (b) is the percentage of PD-1 in CD4+ and CD8+ T cells, ** represents P<0.01, and ns represents no significant difference). DETAILED DESCRIPTION

[0029] In the prior art, RasGRP1 plays an important role in the regulation of T cells and immune response, and RasGRP1 has also become a potential target for the research and development of new immunomodulatory drugs, but there are relatively few reports on the research of RasGRP1 point mutations in the regulation of T cells and immune response. Based on this, the present invention provides a mouse RasGRP1 gene.

[0030] The present invention first performs mutation treatment on mice, and genetically screens the mutant mice to obtain the mutant mice, and finds that the peripheral blood T cell ratio of the mutant mice decreases, while the memory T cell ratio increases. Then, through exon capture and sequencing, it is determined that the nucleotide at position 1083 of exon 9 of the mouse RasGRP1 gene mutates from cytosine C to adenine A, resulting in the corresponding amino acid at position 361 being mutated from aspartic acid to glutamic acid. The mouse RasGRP1 gene provided by the present invention is a new point mutation RasGRP1 gene, which provides a new and available genetic resource for studying the effect of point mutation on the function of the RasGRP1 gene.

[0031] Furthermore, tumor-bearing experiments using mice with RasGRP1 gene point mutations showed that RasGRP1 gene point mutations weakened T cell infiltration in mouse tumors and aggravated their exhaustion phenotype. This fully demonstrates that RasGRP1 is a key gene in tumor immunity and reveals a new regulatory effect of RasGRP1 gene point mutations on T cells.

[0032] The present invention is further described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited thereto; however, these embodiments are only examples and do not constitute any limitation on the scope of the present invention. The details and forms of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the protection scope of the present invention. The experimental methods in the following embodiments, unless otherwise specified, are conventional methods, such as referring to the Molecular Cloning Laboratory Manual (Sambrook J & Russell DW. Molecular cloning: a laboratory manual. 2001) compiled by Sambrook et al., or the instructions provided by the product manufacturer. The experimental materials used in the following embodiments, unless otherwise specified, are purchased from conventional biochemical reagent manufacturers.

[0033] Specific examples of the application of a mouse RasGRP1 gene and a mouse model with a RasGRP1 gene point mutation according to the present invention:

[0034] In order to study the effect of RasGRP1 gene point mutation on its function, the present invention constructed a mouse model of RasGRP1 gene point mutation and conducted in-depth research on its function in tumor immunity. The specific implementation operations are as follows:

[0035] Example 1 Construction of a mouse model with a point mutation in the RasGRP1 gene

[0036] 1. Construction of mice with RasGRP1 gene point mutation

[0037] Mice with point mutations in the RasGRP1 gene were obtained by ENU chemical mutagenesis, and the method was as follows: 30 8-week-old C57BL / 6 male mice were taken as the objects of gene mutagenesis, and ENU was injected intraperitoneally for mutagenesis. According to the injection dose of 90 mg / kg, injections were given once a week for three consecutive weeks. After the last injection until 15 weeks of age, the male mice that had undergone mutagenesis passed the infertility period, and each male mouse was hybridized with a C57BL / 6 female mouse in a 1:1 ratio to construct a family as G0. The first generation of offspring was G1. After the lactation period, the G1 male and female mice mated again to produce G2. The male and female mice of the same litter produced by G2 continued to mate and finally obtained the G3 generation with homozygous mutations. After the G3 generation mice have passed 3 weeks, the males and females are separated into cages, and they can be used as living subjects for subsequent immunophenotyping analysis. The peripheral blood of the G3 generation mice was analyzed for T cell phenotype using flow cytometry, and the results are as follows: Figure 1 and Figure 2 It was found that the proportion and absolute count of T cells in some mice were significantly reduced, while the CD44 hi CD62L low The percentage of memory T cells increased significantly, indicating that a gene mutation had occurred and that this gene mutation had caused changes in the development and differentiation of mouse T cells. These mice with phenotypes were used as the subject of subsequent analysis.

[0038] 2. Identification of the gene mutation site in mice with RasGRP1 gene point mutation

[0039] (1) Exome sequencing to preliminarily confirm point mutation sites

[0040] Three mutant mice with phenotypes and three mice without phenotypes from the same litter were selected, and their genomic DNA was extracted using a kit. The DNA was then sent to BGI for exon capture sequencing. The sequencing results were preliminarily screened according to the following criteria: (1) the mutation site was a missense mutation or nonsense mutation; (2) the mutation site was located in an exon; (3) the mutation site was a homozygous mutation; (4) the function of the gene at the mutation site was predicted to be related to T cell development; (5) the mutation site existed in mice with phenotypes but not in mice without phenotypes. Finally, the RasGRP1 gene point mutation was screened out and met all the above requirements. The results showed that a base in exon 9 of the RasGRP1 gene mutated from cytosine C to adenine A, resulting in the corresponding amino acid at position 361 mutating from aspartic acid to glutamic acid.

[0041] In order to further verify that it is indeed the point mutation of the RasGRP1 gene that causes the immune phenotype changes in the number and activation of T cells, we selected more mice with and without phenotypes from the G3 generation of mice and performed Sanger sequencing verification on the point mutation sites of the RasGRP1 gene:

[0042] (2) Design of sequencing primers for the point mutation site of RasGRP1 gene

[0043] The mutant genes and their mutation sites obtained by exon capture sequencing were searched on the NCBI database website, and the mutant gene fragments were designed in combination with the mouse genome information software Primer3, MGI, BLAST, etc. The upstream and downstream of the fragment were 350-500 bp in total, and the primer synthesis was entrusted to Shanghai Bio-Tech Co., Ltd.

[0044] The primer sequences are as follows:

[0045] F: 5'-GCGAGATGACTGAACTGCTG-3' (shown in SEQ ID NO. 2);

[0046] R: 5'-GCAGAATCCTCCCTCCTCTC-3' (shown in SEQ ID NO. 3);

[0047] The nucleotide sequence of the amplified sequence is shown as SEQ ID NO.4.

[0048] (3) PCR amplification and sequencing

[0049] 1) Prepare the PCR reaction system (Table 1) and set the temperature gradient to select the optimal reaction temperature of the primers;

[0050] 2) Using distilled water as a blank control, amplify the DNA samples in the eight consecutive rows according to the following procedure (Table 2) at the optimal temperature of the primers;

[0051] 3) Take 3 μL of the DNA sample after PCR amplification and 3 μL of 5× Loading Buffer, mix them evenly, use Marker2000 as the band size indicator, run in 1.5% agarose gel, 100V, 30min, and check whether the PCR product is amplified;

[0052] 4) The amplified PCR product was sent to Wuhan Jinkairui Bioengineering Co., Ltd. for sequencing. Figure 3 shown.

[0053] Table 1 PCR amplification reaction system

[0054]

[0055] Table 2 PCR amplification reaction program

[0056]

[0057] Primers were designed for the mutation site of exon 9, and PCR amplification of the target gene was performed. The gel electrophoresis results showed that the size of the PCR product band of the mutant group mice was consistent with that of the control group (e.g. Figure 3 The sequencing results are shown in a). Figure 3 As shown in Figure b, a base in the 9th exon of the RasGRP1 gene mutated from cytosine C to adenine A, causing the corresponding amino acid at position 361 to mutate from aspartic acid to glutamic acid. Comparing the sequencing results with the results of the immunophenotypic analysis, it was found that only when the point mutation site was homozygous, the T cell immune phenotype changed, while when the point mutation site was heterozygous or wild type, the T cell immune phenotype did not change, which further proved that the point mutation of the RasGRP1 gene caused the change in the encoded amino acid, ultimately causing the loss of RasGRP1 function and affecting the development and differentiation of T cells.

[0058] Example 2 Effect of RasGRP1 gene point mutation on tumorigenesis

[0059] In this example, mice with RasGRP1 gene point mutation were used as animal models to conduct tumor-bearing experiments to analyze the effect of RasGRP1 gene point mutation on tumor formation. The specific process is as follows:

[0060] 1) After the Yumm3.3 cell line was expanded to a certain level, it was collected and prepared into a single cell suspension using PBS;

[0061] 2) Take 8-10 week old wild-type and RasGRP1 gene point mutation mice, inject the same number of Yumm3.3 cells subcutaneously, and the injection is considered successful if a clear-border bulge is visible under the mouse skin after injection;

[0062] 3) Depending on the growth of the tumor, the tumor was removed on the 14th day and placed in a 24-well plate filled with 2% RPMI, and the 24-well plate was placed on ice. The liquid on the surface of the tumor was gently blotted with absorbent paper, weighed, and photographed for record;

[0063] 4) The tumor was dissociated into single cells, and white blood cell counts and flow cytometry antibody staining were performed to investigate the infiltration of white blood cells and T cell-related phenotypes. Figures 4 to 6 shown.

[0064] Yumm3.3 cells were simultaneously implanted in wild-type mice and mice with RasGRP1 gene point mutations. The tumor volume was recorded when small protrusions appeared in the tumor 5 days after implantation. On the 17th day after implantation, the tumor was removed from the subcutaneous tissue, impurities on the tumor surface were cut off with small scissors, and the liquid was wiped dry with absorbent paper. The tumor was weighed and the tumor weight was recorded in a horizontal analyzer. The results are shown in Figure 2. Figure 4 As shown in a, when the tumor grew to the 10th day, the tumor in the mutant group grew rapidly, which was different from that in the wild-type control group mice (* represents P < 0.05); Figure 4 b Tumor weight analysis showed that RasGRP1 gene point mutation led to an increase in tumor weight, and the difference was statistically significant (** represents P < 0.01).

[0065] Further, analysis by flow cytometry and flow antibody staining revealed that ( Figure 5 There was no difference in immune cell infiltration after RasGRP1 gene point mutation (P>0.05), but the percentage and absolute count of T cells were significantly reduced (*** represents P<0.01).

[0066] In addition, this embodiment detects the T cell surface exhaustion marker PD-1 by flow cytometry. The flow cytometry results show that (eg Figure 6 As shown in the figure, compared with the control group, the percentage of PD-1 in CD4+T cells increased after RasGRP1 gene point mutation (** represents P < 0.01), and there was no difference in the percentage of PD-1 in CD8+T cells (P > 0.05). The increase in PD-1 expression in T cells of mice with RasGRP1 gene point mutation inhibits T cell activation and cytokine release. Combined with the decrease in the number of T cells in tumor cells of mice with RasGRP1 gene point mutation, the above results indicate that the RasGRP1 gene point mutation weakens the anti-tumor effect of T cells.

[0067] The above results show that tumor cells have a clear growth advantage in mice with RasGRP1 gene point mutation. Therefore, it can be used as a model mouse for easy acquisition of tumors for anti-tumor drug screening and tumor treatment research.

[0068] Finally, it is noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A mouse RasGRP1 gene, characterized in that: The nucleotide sequence of exon 9 of the RasGRP1 gene is shown in SEQ ID NO.

1.

2. Application of a mouse model with a RasGRP1 gene point mutation in tumor immunity research, characterized in that: The nucleotide at position 1083 of exon 9 of the RasGRP1 gene of the mouse model mutates from cytosine C to adenine A.

3. The use of the mouse model with RasGRP1 gene point mutation in tumor immunity research according to claim 2, characterized in that: The tumor immunity study included the increase in tumor volume and weight after tumor bearing in mouse models.

4. The use of the mouse model with RasGRP1 gene point mutation in tumor immunity research according to claim 2, characterized in that: The tumor immunity study included the reduction of T cell percentage and absolute count in tumors after tumor bearing in mouse models.

5. The use of the mouse model with RasGRP1 gene point mutation in tumor immunity research according to claim 2, characterized in that: The tumor immunity study includes CD4 + The percentage of PD-1 in T cells was increased.